Innovative TRAF-STOP Treatment Reduces the Progression of Established Atherosclerosis and Induces a Stable Plaque Phenotype

Schermafbeelding 2018-02-23 om 14.28.56

In this paper the LMU (Munich) and AMC (Amsterdam) groups show that blocking CD40-TRAF6 interactions by Small Molecule Inhibitors (TRAF-STOP) treatment strongly reduces  atherosclerosis by preventing activation of classical monocytes, leukocyte recruitment, and macrophage activation and migration in the arterial wall.

Schermafbeelding 2018-02-23 om 14.28.09

TRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis and have the potential to become a future therapeutic for atherosclerosis. (J Am Coll Cardiol 2018;71:527–42)

Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.